三生国健(688336) - 2025 Q4 - 年度业绩预告

Revenue Projections - The company expects to achieve approximately CNY 4.2 billion in revenue for the year 2025, an increase of about CNY 3.006 billion compared to the previous year, representing a growth rate of approximately 251.76%[5] Profit Projections - The projected net profit attributable to the parent company for 2025 is around CNY 2.9 billion, which is an increase of approximately CNY 2.195 billion year-over-year, reflecting a growth rate of about 311.35%[5] - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is approximately CNY 2.8 billion, an increase of about CNY 2.554 billion compared to the previous year, indicating a growth rate of approximately 1,038.21%[5] - The previous year's net profit attributable to the parent company was CNY 705 million, with a net profit after deducting non-recurring gains and losses of CNY 246 million[8] Contributing Factors - A significant factor contributing to the performance increase is the collaboration with Pfizer Inc., which resulted in a licensing fee payment of approximately CNY 2.89 billion recognized as revenue[10] Financial Reporting - The earnings forecast has not been audited by a registered accountant, and the company assures that there are no major uncertainties affecting the accuracy of this forecast[12] - The data provided is preliminary and the final audited financial data will be disclosed in the official 2025 annual report[13]